Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exploiting macropinocytosis for drug delivery into KRAS mutant cancer.

Theranostics - 1 Jan 2022

Liu Huiqin, Qian Feng

Abstract excerpt

KRAS mutations are one of the most common gene mutations linked to cancer, presenting in approximately 25% of all tumors, especially pancreatic, lung, and colorectal cancers. Mutant KRAS has long been considered an undruggable target, stalling progress in direct KRAS targeting for many years, while targeted drug delivery into KRAS mutant cells utilizing their transformed metabolic behavior might present an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Cellular transport and secretion
Share to Drug Delivery Systems

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Neoplasms

Share to Phagocytosis and Immune Regulation

Share to Pinocytosis

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 35154489
DOI: 10.7150/thno.67889
PMCID: PMC8771556

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exploiting macropinocytosis for drug delivery into KRAS mutant cancer.PMID 35154489Read ↗

KRAS mutation-driven enhanced macropinocytosis: using albumin as a trojan horse for delivering nanomedicine.Semantic proximity Read ↗

Survival strategies of cancer cells: the role of macropinocytosis in nutrient acquisition, metabolic reprogramming, and therapeutic targetingSemantic proximity Read ↗

Intracellular nanoparticle delivery by oncogenic KRAS-mediated macropinocytosisSemantic proximity Read ↗

The Dual Role of Macropinocytosis in Cancers: Promoting Growth and Inducing Methuosis to Participate in Anticancer Therapies as TargetsSemantic proximity Read ↗

Dual blockade of macropinocytosis and asparagine bioavailability shows synergistic anti-tumor effects on KRAS-mutant colorectal cancer.Semantic proximity Read ↗

Novel selective inhibitors of macropinocytosis-dependent growth in pancreatic ductal carcinoma.Semantic proximity Read ↗

Stimulating macropinocytosis of peptide-drug conjugates through DNA-dependent protein kinase inhibition for treating KRAS-mutant cancer.Semantic proximity Read ↗

Gold Nanoparticles Inhibit Macropinocytosis by Decreasing KRAS Activation.Semantic proximity Read ↗

Macropinocytic dextran facilitates KRAS-targeted delivery while reducing drug-induced tumor immunity depletion in pancreatic cancer.Semantic proximity Read ↗

CX-4945 (Silmitasertib) Induces Cell Death by Impairing Lysosomal Utilization in KRAS Mutant Cholangiocarcinoma Cell Lines.Semantic proximity Read ↗

Catabolic pathways regulated by mTORC1 are pivotal for survival and growth of cancer cells expressing mutant Ras.Semantic proximity Read ↗

An Emerging Role of KRAS in Biogenesis, Cargo Sorting and Uptake of Cancer-Derived Extracellular VesiclesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.